阿德福韦酯治疗失代偿期乙型肝炎肝硬化临床观察  

Therapeutic effects of adefovir dipivoxil on HBV decompensated cirrhosis

作　　者：陈叶青[1] 周国华[1] 刘树旗[1] 周红宇[1] 王为[1] 王丽姣[1] 冷明芳[1] 

机构地区：[1]解放军169医院消化内科,湖南衡阳421002

出　　处：《实用药物与临床》2012年第9期565-566,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床效果。方法 40例失代偿期乙型肝炎肝硬化患者,随机分为治疗组和对照组,每组20例。对照组用常规方法治疗,治疗组在常规治疗基础上加用阿德福韦酯10 mg,口服,1次/d,治疗96周。观察治疗前后肝功能变化、HBV-DNA定量、生存时间及不良反应。结果治疗组血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)、胆红素(TBIL)、白蛋白(ALB)、胆碱酯酶(CHE)等指标均优于对照组,两组之间差异有统计学意义(P<0.01)。治疗组有18例患者HBV-DNA转阴,转阴率为90%,而对照组仅有2例患者转阴,转阴率为10%,两组转阴率比较差异有统计学意义(P<0.01)。治疗组治疗期间未发现与服用阿德福韦酯有关的不良反应。结论阿德福韦酯治疗失代偿期乙型肝炎肝硬化,可以显著改善肝功能,延长患者生存时间,其疗效肯定,不良反应少,患者耐受性好,值得临床推广应用。Objective To explore the clinical effect of adefovir dipivoxil on HBV decompensated cirrhosis. Methods 40 patients with HBV decompensated cirrhosis were randomly divided into 2 groups：treatment group and control group,20 patients for each group. Treatment group was treated with adefovir dipivoxil and normal treatment for 96 weeks ; control group was treated with normal treatment. The changes of liver function, 1-IBV-DNA, survival time and adverse reaction were observed. Results The patients of treatment group were better than control group in ALT, DBIL,albumen and CHE. There were significant differences between the two groups（P 〈0. 01 ）. The HBV-DNA of 18 patients in treatment group were converted to negative, the conversion rate was 90% ;and in control group only 2 patients＇s HBV-DNA were converted to negative, and the conversion rate was 90%. There were significant differences between the two groups （ P 〈 0. 01 ）. There was no adverse reaction in treatment group. Conclusion Adefovir dipivoxil can improve liver function,prolong survival time, it is a safe and effective method with little adverse reactions in treating HBV decompensated cirrhosis.

关 键 词：失代偿期肝硬化 乙型肝炎 阿德福韦酯 

分 类 号：R512.62[医药卫生—内科学]